A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

AZ and Daiichi announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced form of ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

Tucatinib and trastuzumab work by blocking a protein known as human epidermal growth factor receptor 2 (HER2) in cancer cells ...

NPPA asks companies to revise MRP of three anti-cancer drugs and submit information: Gireesh Babu, New Delhi Tuesday, October 29, 2024, 16:15 Hrs [IST] The National Pharmaceutical ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...